Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

NCT07713732 is registered in ClinicalTrials.gov with Treeline Biosciences, Inc. as lead sponsor.

NCT NCT07713732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07713732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Lead sponsor
Treeline Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 5, 2026
Completion date
August 29, 2030
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesotheliomas (mpm), neuroendocrine cancer, small cell lung cancer ( sclc ), synovial sarcomas